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1. Introduction 
Glaucoma is an irreversible chronic disease; thus, management is a great challenge. The 
main goal of treatment is to prevent further nerve fibre damage. The present modes of 
treatment include pressure-lowering medications, laser treatment, and surgical 
interventions, all of which aim to reduce IOP. Diversion of aqueous humour outflow 
through an iatrogenic fistula to the sub-conjunctival space is the principle underlying 
glaucoma surgery. Surgical intervention provides sustainable constant IOP reduction but 
not without intra- and postoperative complications (Migdal et al, 1994; Musch et al, 2009). 
In fact, glaucoma surgery hastens cataract formation, which may necessitate further 
surgical intervention (Musch et al, 2009; AGIS group, 2000). Surgical equipment, a proper 
operating theatre, and an experienced surgeon increase the cost of filtration surgery. The 
invasiveness of the procedure interrupts the natural defence mechanism of the eye, 
increasing the risk of infection. Laser treatment is less invasive and is associated with a 
lower risk of infection. Similar to the filtration surgery, it is a permanent procedure and 
does not require a high technology environment but requires an expensive high-
maintenance laser machine. However, the pressure-lowering effect is insufficient and 
temporary (Glaucoma Laser Trial Research Group, 1995). Manipulation of aqueous 
humour production and outflow is the mainstay mechanism of topical pressure-lowering 
medications. Topical medications are widely available in industrialised nations, are non-
invasive and easily transportable. In addition, they are relatively easy to instil without the 
need for special equipment or a high technology environment. Importantly, unlike 
surgical or laser treatment, it is non-permanent and easily discontinued if it is ineffective 
or produces unwanted side effects.  
Topical pressure lowering medications was previously known as topical antiglaucoma 
drugs. However, many glaucomatologist deem the term inappropriate. The medications do 
not at all reverse the condition or totally halt the progression of glaucoma. In this chapter, 
the term pressure lowering medications or drugs will be used. The sprouting of new more 
effective pressure lowering medications has widened the choice of medications and at time 
cause difficulty in the selection of medication. Table 1.0 provide an overview on commonly 
available pressure lowering medication in the market currently. A guideline on selection of 
topical pressure lowering medications will be discussed in this chapter. 
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Group Mode of action Drugs 
(concentration) 
Dose IOP 
reduction 
Parasympathomimetics 
 
 
Sympathomimetics 
 
 
 
 
 
 
 
 
 
Carbonic anhydrase 
inhibitor 
 
 
Beta adrenoreceptor 
antagonist 
 
 
 
 
 
 
 
 
 
 
Prostaglandin analog 
Increased aqueous 
outflow 
 
Non-selective 
Decrease aqueous 
production and 
increase outflow 
 
Selective 
Decrease aqueous 
production 
 
 
Decrease aqueous 
production 
 
 
Non-selective 
Decrease aqueous 
production 
 
 
 
 
 
Selective 
Decrease aqueous 
production 
 
 
Pilocarpine 
(0.25-4%) 
 
Epinephrine 
(0.25-2.0%) 
Dipiverfin 
(0.1%) 
 
Apraclonidine 
(0.5-1.0%) 
Brimonidine 
(0.2%) 
 
Dorzolamide 
(2%) 
Brinzolamide 
(1%) 
 
Timolol  
(0.1, 0.25, 0.5%) 
Levobunolol 
(0.25, 0.5%) 
Timolol GFS 
(0.25, 0.5%) 
 
 
Betaxolol 
(0.25, 0.5%) 
 
Latanoprost 
(0.005%) 
Travaprost 
(0.004%) 
Unoprostone 
(0.12, 0.15%) 
 
Bimatoprost 
(0.03%) 
TID  
or 
QID 
TID 
 
BD 
 
 
BD or 
TID 
BD 
 
 
BD or 
TID 
 
 
 
BD 
 
 
 
Once 
a day 
 
 
BD 
 
 
Once 
a day 
 
 
 
 
 
Once 
a day 
20-25% 
 
 
 
 
 
 
 
20-25% 
 
 
 
 
15-20% 
 
 
 
 
20-25% 
 
 
 
 
 
 
 
15-20% 
 
 
25-30% 
 
 
 
 
 
 
25-30% 
Table 1.0. Commercially available topical pressure lowering drugs  
2. Beta antagonists 
The potential benefit of systemic ǃ-adrenoreceptor antagonists in lowering IOP was initially 
evaluated and intravenous propanolol was found to be the most effective (Philips et al, 
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1967). The profound corneal anaesthesia induced by propanolol, however, outweighs its 
potential utility. Intensive ophthalmic research eventually led to the introduction of topical 
timolol. In 1978, topical timolol revolutionized glaucoma management and is now the first-
line treatment for glaucoma.  
Topical ǃ-blocker acts predominantly by decreasing aqueous humour production without 
any effect on outflow capacity, despite the presence of ADRB2 in the trabecular meshwork 
(Coakes and Brubaker, 1978; Yablonski and Zimmerman, 1978; Sonntag et al, 1978). ǃ-
Blocker action is predominantly mediated by the  ADRB2 receptor, abundantly found in the 
ciliary epithelium and ciliary body. Aqueous humour is produced by ciliary bodies through 
ultra-filtration and active secretion by the ciliary epithelium. The reversible ǃ-blocker 
binding prevents binding of catecholamine that in turn prevents activation of intracellular 
adenylate cyclase and reduces the intracellular concentration of cAMP at the ciliary body. 
Through an unknown mechanism, this process reduces aqueous humour production 
(Neufeld, 1979). The basal level of cAMP is maintained, as is the response to other 
transmitters. cAMP is an important second messenger in the intracellular cascade. Since the 
understanding of aqueous humour production is imprecise, the mechanism of action of 
topical ǃ-blocker remains unknown.  
ǃ-blocker has a less potent effect on ǃ1-adrenoreceptor in decreasing cAMP synthesis 
(Juzych and Zimmerman, 1997). Serotonin receptor, particularly 5-HT1A, is abundant in the 
iris and ciliary body and has a similar molecular structure as ADRB2 receptor, but has a 
negative impact on the adenylyl-cyclase cAMP cascade (Osborne and Chidlow, 1996). 
Timolol demonstrated high affinity towards 5-HT1A in the ciliary process of rabbits, which 
further supports the effect of timolol as a suppressor of aqueous humour production 
(Osborne and Chidlow, 1996). 
Although the classic association of reduced cAMP synthesis and aqueous humour 
production is widely accepted, other evidence disputes this postulation. Schmitt et al (1980) 
found no association between decreased cAMP and the pressure-lowering effect of ǃ-
blockers on rabbits. Drugs that increase intracellular cAMP such as forskolin and cholera 
toxin also reduce the IOP, which contradicts the previous popular hypothesis (Caprioli et al, 
1984). Another hypothesis postulated that the reduction of aqueous humour formation is 
achieved by direct inhibition of adrenergic stimulation of the secretory ciliary epithelium by 
endogenous epinephrine (Topper and Brubaker, 1985). Decreased ocular blood flow 
induced by ǃ-blockers provides another alternative hypothesis. The effect of ǃ-blockers on 
the vascular smooth muscle of the ciliary body inhibits vasodilatation and induces 
vasoconstriction of ciliary arterioles, which reduces capillary perfusion and stromal ultra-
filtration (Vareilles et al, 1977). Reduction of aqueous humour production is an indirect 
consequence of decreases ocular blood flow (Watanabe and Chiou, 1983). There is also direct 
evidence that dopamine plays a role in ocular blood circulation. Haloperidol, a dopamine-
blocking agent, reduces IOP.  
For more than 3 decades, the topical ǃ-blockers, particularly timolol, have been proven 
effective ocular hypotensive drugs in many types of glaucoma. Currently, there are five 
topical beta blockers available worldwide; timolol maleate, betaxolol hydrochloride, 
levobunolol hydrochloride, carteolol hydrochloride and metipranolol (Table 1.1). Although 
the aqueous solution of timolol maleate is widely used but recently the gel forming solution 
has been introduced and well accepted. Gel forming solution is prepared from purified 
P.elodea cell wall that forms gel solution once in contact with monovalent and divalent 
cations in tear film. This novel ophthalmic vehicle provides similar pressure lowering effect 
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as the aqueous form with just once a day dosing (Shedden et al, 2001). It is believed to 
reduce the possible systemic adverse effects but with higher reported incidence of transient 
blurring of vision (Dickstein et al, 2001; Stewart et al, 1999). Topical beta blockers are 
inexpensive especially in the generic form that further increased their popularity especially 
in developing countries. It is still the treatment of choice in many parts of the world.  
 
 
Property Timolol Betaxolol Levobunolol Carteolol Metipranolol 
Concentrations (%)
 
Preservatives 
 
 
Beta blocker potency* 
 
Serum half life (hrs) 
 
Cardioselective 
 
Intrinsic 
sympathomimetic 
 
Ocular discomfort 
 
Systemic side effect 
 Decrease heart rate 
 Respiratory 
impairment 
 Hyperlipidemia 
 
Ocular perfusion 
0.25, 
0.5 
 
BAC#  
0.01% 
 
4.7 
 
3-5 
 
- 
 
- 
 
++ 
 
 
++ 
++ 
+ 
 
± 
0.25, 0.5
 
BAC# 
0.01% 
 
1.0 
 
12-20 
 
++ 
 
- 
 
+++ 
 
 
± 
± 
? 
 
± 
0.25, 0.5
 
BAC# 
0.004% 
 
14.6 
 
6 
 
- 
 
- 
 
++ 
 
 
++ 
++ 
? 
 
? 
1.0
 
BAC#  
0.005% 
 
10.0 
 
3-7 
 
- 
 
++ 
 
± 
 
 
+ 
+ 
- 
 
± 
0.3 
 
BAC#  
0.004% 
 
1.8 
 
2 
 
- 
 
- 
 
+ 
 
 
++ 
++ 
? 
 
? 
* beta blockade potency as compared to propanolol (propanolol=1)  
#BAC: benzylkonium chloride 
? No data available or inconclusive data 
 
Table 1.1. Properties of beta blockers 
2.1 Topical timolol 
Topical timolol is a lipophilic, non-cardio-selective ǃ antagonist without intrinsic 
sympathomimetic activity. It also lacks the ability to act as partial agonist and lacks 
membrane-stabilizing ability. Its chemical name is (-)-1-(tert-butylamino)-3-[4-morpholino-1, 
2, 5-thiadiazol-3-yl] oxy]-2 propanol maleate (1:1) (salt). The asymmetrical carbon atom in its 
structure forms a laevo-isomer (Figure 1.3). The optical rotation of timolol maleate is 
 25°405nmǂ in1.0NHCI(C - 5%) = -12.2°(-11.7°to- 12.5°)  with a molecular weight of 432.50. 
It is an enantiomer; D- and L-enantiomers are stereo-isomers that are non-super-imposable 
mirror images of each other.  
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Timolol maleate is a white crystalline powder soluble in water, methanol, and alcohol, with 
a pKa of approximately 9 in water at 25ºC. It is available as a sterile, isotonic, buffered 
aqueous solution with pH approximately 7.0 and osmolarity of 274–328 mOsm. There are 
also inactive ingredients such as monobasic and dibasic sodium phosphate, sodium 
hydroxide for pH adjustment, and water for injection. Benzalkonium chloride 0.01% is 
added as a preservative. Timolol maleate as the pure chemical is extremely stable to light 
and temperature, but the formulated topical form is less stable with a shelf life of 2 years.  
 
 
Fig. 1.0. Chemical structure and formula of timolol maleate 
The ocular hypotensive effect of timolol is more profound when administered orally but 
significant effect is also achieved topically. Although the ocular hypotensive effect of topical 
timolol is achieved at a concentration as low as 0.008%, the optimal therapeutic dose is 
0.25% and 0.5% twice daily in aqueous solution. The active ingredient in each millilitre of 
0.25% of timolol maleate contains 2.5 mg of timolol (3.4 mg of timolol maleate) and each 
millilitre of 0.5% contains 5 mg of timolol (6.8 mg of timolol maleate). The concentration of 
timolol in the anterior chamber reaches 1–2 µM (8–100 ng/mL) after an hour of topical 
instillation, which is much higher than the minimum amount required to bind ADRB2 in the 
ciliary body (Philips et al, 1985). Thus, the pressure-lowering effect is achieved just 20 to 30 
minutes after instillation with the peak seen 2 hours post instillation (Zimmerman and 
Kaufman, 1977). This is followed by further pressure reduction that is sustained up to 24 
hours. Surprisingly, the half-life of topical timolol is just 1.5 hours (Schmitt et al, 1980). 
Reversible binding of timolol to ocular melanin provides a reservoir for slow release of the 
active drug and is responsible for prolonging the pressure-lowering effect of timolol despite 
its short half-life. Animal studies have shown that timolol has a high affinity for and binds 
easily to melanin. Dark-pigmented rabbits demonstrated higher concentration of timolol 
maleate in the iris ciliary body when compared to albino rabbits, reducing the amount of 
active ingredient available for pharmacological action (Menon et al, 1989). Melanin near to 
the site of pharmacological action did not inactivate the active drug. Paradoxically, melanin 
competitively inhibits timolol. The net effect is that highly pigmented eyes require a higher 
concentration than less pigmented eyes, which is reflected in clinical observations in Asians 
and Africans (Ong et al, 2005; Otaleju and Ajayi, 1999; Katz and Berger, 1979).  
Zimmerman and Kaufman (1977) reported the first 24-hour dose response to topical timolol 
0.25% and 0.5% was similar. Maximum pressure reduction was reported to be nearly 40% in 
glaucoma patients treated with 0.5% topical timolol in short- and long-term dose-response 
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studies (Zimmerman and Kaufmann, 1977; Boger et al, 1978; Lin et al, 1979). The pressure-
lowering effect is best in daytime and poor at night, when aqueous humour production is 
reduced to less than half. In its early days, the effectiveness of timolol was compared only to 
topical pilocarpine and epinephrine, and was found to be significantly more effective with 
the added advantage of less frequent dosing (Boger et al, 1978; Zimmerman and Boger, 
1979). The effectiveness of timolol has earned it status as the ‘gold standard’ used as the 
comparator for other new drugs that have flourished the glaucoma pharmaceutical market.  
Topical timolol is effective in nearly all types of glaucoma including refractory glaucomas 
such as neovascular, aphakic, and uveitic glaucoma (Weber, 1981, Lin et al, 1979). Perhaps, 
due to its suppressive effect on aqueous humour production, it is also effective in angle-
closure glaucoma (Lass and Pavan-Langston, 1979; Chew et al, 2004). Long-term treatment 
with timolol has been proven effective, but the effect is not sustained in more than half of 
patients after 5 years (Watson et al, 2001). Boger (1979) reported short-term escape and long-
term drift phenomena in certain individuals. Upregulation of ADRB2 receptors in the iris 
and ciliary body is believed to be responsible for blunting the effect of timolol after short-
term treatment (Boger, 1979). A meta-analysis comparing a wide range of topical anti-
glaucoma drugs and prostaglandin analogue found that timolol is as effective as 
prostaglandin analogue in providing good IOP reduction at peak and trough (van de Valk et 
al, 2005). Prostaglandin analogue is slightly but not significantly better than timolol in 
pressure-lowering effectiveness.  
Similar reduction of pressure by timolol was also reported in the contralateral, untreated eye 
(Dunham et al, 1994; Piltz et al, 2000). Absorption of timolol by the nasopharyngeal mucosa 
has raised concerns of potentially life-threatening side effects following topical 
administration (Passo et al, 1984; Diggory and Franks, 1997). The elderly and those with 
cardio-respiratory impairment are at risk, and prescribing timolol in these patients must be 
done with caution (Diggory et al, 1998; Diggory et al, 1994; Leier et al, 1986). In spite of great 
concern regarding the systemic side effect of timolol but there is no evidence suggesting 
increase in mortality in patients on topical timolol therapy (Müsken et al, 2008). Although 
timolol has some effects on hypoglycaemia and hyperlipidaemia, the effect is minimal with 
low clinical importance (Coleman et al, 1990; Shorr et al, 1997). Decreased libido, depression, 
and hallucination are among the reported side effects of timolol (Lama, 2002). Due to the 
potential cardiorespiratory side effect,timolol is contraindicated in asthmatic or those with 
history of asthma, severe chronic obstructive pulmonary diseases, severe heart block, overt 
cardiac failure, bradycardic patients and those with history of allergic to timolol or its 
preservatives.  
The introduction of gel-forming timolol solution has lessened its systemic effect (Shedden et 
al, 2001). Timolol gel-forming solution (GFS) increases the viscosity of the drug, promotes 
ocular bioavailability, and facilitates ocular drug penetration. The prolongation of ocular 
contact depends on the gel formulation, which acts as a physical barrier to drainage or as a 
viscosity promoter. The gel in Timolol XE 0.5% promotes viscosity and bleb formation, 
which creates a temporary plug in the inner canthus and impedes timolol drainage through 
the punctum. Once-daily dosing of timolol GFS provides a similar pressure-lowering effect 
as timolol maleate in aqueous form with twice-daily instillation in glaucoma and ocular 
hypertensive patients (Roselund, 1996; Shedden et al, 2001). Plasma concentrations of 
timolol GFS are significantly lower than timolol ophthalmic solution, which perhaps 
explains the reduced systemic side effects associated with the gel solution (Shedden et al, 
2001; Dickstein et al, 2001; Uusitalo et al, 2006). Blurred vision upon instillation of timolol in 
gel solution and ocular discomfort were reported in many patients (Shedden et al, 2001).  
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Ocular allergic reaction is one of the commonest ocular side effects following topical timolol 
instillation, which can manifest as blepharoconjunctivitis, erythema and edema of the 
eyelids (Akingbehin and Sunder Raj, 1990).  Allergic reaction can occur at any duration of 
treatment and as early as the first month. Timolol has similar ability as topical propanolol to 
induce corneal anaesthesia but at lesser extent (van Buskirk, 1980). Superficial punctuate 
keratitis has been reported and may lead to epitheliopathy and corneal epithelial erosions. 
Dry eye and reduce break up time has also been documented in patients treated with topical 
timolol (Kuppens EV et al, 1992; Kuppens EV et al 1995; Fasina O et al, 2008).  
2.2 Betaxolol 
Betaxolol is a cardioselective beta antagonist with relative specificity for ǃ1-adrenoceptor 
and without intrinsic symapthomimetic activity. Based on available evidences, ǃ1-
adrenoceptors are thought to be involved in regulating heart rate, rhythm and force 
(Murphree and Saffitz, 1988). However, the distribution of subtype of ǃ-adrenoceptors is 
more complex than it is believed to be (Carstairs et al, 1985; Satoh et al, 1990). It is believed 
that the selectivity of certain drug during pre-clinical experiments may not truly reflective in 
the actual clinical setting.    
Betaxolol is a safer alternative for glaucoma patients with mild respiratory impairment due 
to asthma or other chronic obstructive pulmonary diseases. However, there are reported 
cases of pulmonary side effect in patients on betaxolol especially in high risk population 
(Diggory et al, 1994). Even in healthy volunteers, systemic side effects are still presence but 
with lesser degree as compared to metapronalol and timolol (Bauer et al, 1991). There was 
still unchanged in respiratory symptoms after changing from timolol to betaxolol (Diggory 
et al, 1994). Perhaps, this is due to the presence of ǃ1 adrenoreceptor in human lung tissue 
with the ratio of 1:3 (ǃ1: ǃ2) (Carstairs et al, 1985). Betaxolol does not confer total protective 
effect in patients with respiratory impairment and need to prescribe with caution. Perhaps, 
prostaglandin analogues provide better protective effect for those with respiratory 
impairment. 
Similar to timolol, betaxolol acts as aqueous suppression through unknown mechanism. 
However, betaxolol is less potent than timolol as pressure lowering medication. Timolol and 
levobunolol provides approximately 2 mmHg more IOP reduction compared to betaxolol 
(Allen et al, 1986; Gaul et al, 1989). Smaller amount of ǃ1 adrenoreceptors in the ocular tissue 
especially ciliary body as compared to ǃ2 adrenoceptors is postulated to be the causative 
factor for lack of effectiveness of betaxolol. Topical instillation of betaxolol 0.5% results in 
plasma level of approximately 0.5ng/ml or half that of timolol 0.25% (Vuori et al, 1993). 
Betaxolol is the drug of choice in Early Manifest Glaucoma Trial (EMGT). EMGT reported 
IOP reduction of 25% from baseline with combination of laser trabeculoplasty and topical 
betaxolol treatment (Heijl et al, 2002). Treatment has significantly reduced the progression of 
visual field in patients with early stage of glaucoma. 
However, the striking benefit of betaxolol than other topical beta blocker is its potential 
neuroprotective effect. Neuroprotective effect of betaxolol is believed to be due to its ability 
to block calcium channels on the vessels and retinal ganglion cells (Yu et al, 1999, Wood et 
al, 2003). It is postulated that the effect of betaxolol on calcium channels is independent of 
the ǃ-adrenoceptor (Setoguchi et al, 1995). In addition, betaxolol also inhibits glutamate 
(Hong et al, 2003; Chen et al, 2007).The effect of betaxolol in optic nerve head vasculature is 
also believed to improve the perfusion and reperfusion of the optic nerve head (Hester et al, 
1994, Cheon et al, 2003). However, the clinical effectiveness of betaxolol as neuroprotective 
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is rather inconclusive. Although there are evidence suggesting the effectiveness of betaxolol 
in halting the progression of glaucoma but the association is not strong enough (Messmer et 
al, 1991; Araie et al, 2003). 
2.3 Other beta antagonists 
Levobunolol, metipranolol and carteolol are non-selective topical ǃ blockers without 
significant intrinsic sympathomimetic activity, which require metabolization to their active 
metabolites to achieve their function. Levobunolol is metabolized to dihydrobunolol that 
has similar potency as timolol at ǃ2 adrenoreceptor found in the iris and ciliary body (Wax 
and Molinoff, 1987). It is available in 0.25% and 0.5%, effective both as once daily dosing as 
well as twice daily (Wandell et al, 1988). Metipranolol is metabolized to des-acetyl-
metipranolol. It is an effective as pressure lowering effect with concentration ranging from 
0.1% to 0.6% (Mirza et al, 2000). There is also evidence of increase in retinal perfusion 
pressure and blood flow in patients treated with metipranolol (Wolfs et al, 1998). Peculiarly, 
drug induced anterior uveitis has been associated with metipranolol treatment (Watanabe 
and Hodes, 1997). Similar to levobunalol and metipranolol, carteolol is metabolized to active 
metabolite, 8-hydroxycarteolol. Unlike other topical ǃ blockers, carteolol possesses intrinsic 
sympathomimetic activity. Although carteolol is less irritating than 0.5% timolol but 
moderate corneal anaesthesia has been reported (Bartlett et al, 1999). Carteolol appears to 
have negligible effect on serum lipid profile (Stewart et al, 1999).   
3. Prostaglandin analogues 
For 25 years, topical timolol maleate has been widely accepted as the treatment of choice for 
glaucoma. It is undoubtedly efficacious in almost all types of glaucoma. A lack of intolerable 
side effects in comparison to topical non-selective sympathomimetics and mitotics further 
contributed to the popularity of topical timolol. The quest for more potent agents began in 
the early 1980s. During the frenzy of interest in prostaglandin’s possible ocular anti-
inflammatory effects and potential therapeutic role, prostaglandin was infused into 
cannulated experimental animal eyes and was found to cause ocular hypertension with 
breakdown of the blood-aqueous barrier (Bito et al, 1989a). Accidentally, the ocular 
hypotensive effect was achieved with a low concentration of topical prostaglandin with 
breakdown of the blood-aqueous barrier even without cannulation. Naturally occurring 
prostaglandins are relatively polar, hydrophilic molecules that poorly cross biological 
membranes due to their carboxylic acid moiety and several hydroxyl groups. Prostaglandin 
effects differ between species (Bito et al, 1989b). Different prostanoids have different side 
effects on the human eye, consistent with the reported multiplicity and low selectivity of 
naturally occurring prostaglandin for different subtypes of prostanoids (Woodward et al, 
1997).  
The was a major setback in the first experiment with topical prostaglandin in human 
volunteers using a high concentration (200 µg) tromethamine salt form of PGF2ǂ, which 
resulted in severe ocular hyperaemia, ocular pain, and headache (Giuffre, 1985). Lower 
concentrations (up to 100-fold) were found to potentiate better ocular hypotensive effects 
with esterification of the prostaglandin carboxylic acid group, which is the basis of the pro-
drug principle (Kerstetter et al, 1988). Esterification of the carboxylic acid reduces polarity 
and facilitates penetration of the prodrug through biological lipid membranes. The prodrug 
is then converted to free acids to activate the specific FP receptors once it crosses the corneal 
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epithelium in the specific direction known as orthrorectified transport or the slow release 
system, which is ideal for chronic therapy in glaucoma and minimizes unwanted ocular and 
systemic side effects (Figure 1.2).  
 
 
 
Fig. 1.2. Chemical structure of major topical prostaglandin analogue pro-drugs and their 
hydrolyzed free acids. 
After more than 2 decades in search of a topical prostaglandin with an acceptable 
therapeutic index, Unoprostone (13, 14-dihydro-15-keto metabolite of PGF2ǂ) with the trade 
name of Rescula (Ciba Vision, Duluth GA) was made commercially available in Japan. The 
drug failed to gain popularity worldwide due to lack of efficacy and the requirement for 
twice-daily administration. In 1996, latanoprost (13, 14-dihydro-17-phenyl-18, 19, 20-trinor-
PGF2ǂ-isopropyl ester) was marketed as Xalatan (Pfizer Inc, New York) and gained approval 
worldwide. Later, travoprost (Travatan; Alcon) and bimatoprost (Lumigan; Allergan) were 
introduced. Unlike latanoprost and travoprost, bimatoprost has been controversially known 
as prostamide owing to the presence of a C1 ethyl amide group that activates different 
receptors. However, topical prostaglandin analogues are believed to achieve pressure-
lowering effects by increasing uveoscleral outflow without any effect on aqueous humour 
production (Toris et al, 1993). However, their effect on the trabecular meshwork remains 
unclear (Oh et al, 2006; Johnson et al, 2010). There was no statistically significant difference 
in efficacy between the 3 commercially available topical prostaglandin analogues but there 
was a reported borderline increased incidence of ocular hyperaemia with bimatoprost (van 
Not 
available 
for patient 
use 
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de Valk et al, 2005; Zimmerman et al, 2009). Bimatoprost has the edge in effectiveness but 
with slightly more pronounced side effects (Cracknell and Grierson, 2009). 
Topical prostaglandin analogues have changed the paradigm of glaucoma management, 
most notably with the declining rate of glaucoma surgeries in the late 1990s (Bateman et al, 
2002). Currently, due to their efficacy and better tolerability, topical prostaglandin 
analogues are replacing topical timolol as the first-line drug of choice in glaucoma 
management (Holmstrom et al, 2006). It is amazing that low lipid solubility drugs in low 
concentrations can achieve such an impact in glaucoma management.  
3.1 Topical latanoprost 0.005% 
Topical prostaglandin analogue PhXA34 (13, 14-dihydro-17-phenyl-18, 19, 20-trinor-PGF2ǂ-
isopropyl ester) known as latanoprost, differs from the naturally occurring PGF2ǂ, where 
C18 to C20 have been substituted by a benzene ring, the double bond between C13 and C14 
has been saturated, and the carboxylic acid moiety on C1 has been esterified with 
isopropanol (Figure 1.7). The molecular weight of latanoprost is 432.6 and the hydrolysed 
compound (free acid) is 390.5 (Stjernschantz and Alm, 1996). The octanol-water partition 
coefficient is 4.3 at pH 7.4, with poor solubility in water. It is available as a colourless to 
slightly yellow oil solution in 0.005% concentration (50µg/ mL) preserved with 0.02% 
benzalkonium chloride. It is commercially available in 5 mL plastic bottles (2.5 mL 
latanoprost solution), which requires refrigeration to maintain a temperature of 2 to 8°C for 
unopened bottles. The recommendation for refrigeration was made based on experimental 
finding in the laboratory. There was 10% degradation after extreme exposure to 50°C for 198 
hours (Morgan et al, 2001). In clinical practice, it is safe to transport and store at room 
temperature without reducing the effectiveness of the drug (Novak and Evans, 2001; Varma 
et al, 2006). Latanoprost can be prescribed as either evening or morning once-daily dosing 
but evening dosing is more efficacious (Alm and Stjernschantz, 1995). 
Latanoprost is a selective FP receptor agonist with marginal spillover effect on other 
prostanoid receptors, resulting in fewer unwanted side effects. Naturally occurring PGF2ǂ 
has greater affinity than latanoprost for the FP receptor but also interacts with other 
prostaglandin receptors, which is partly responsible for side effects such as iritis and 
conjunctival hyperaemia (Alm and Stjernschantz, 1997). As a prodrug, it is relatively 
inactive until the hydrolyzation of the isopropyl ester to free acid in the cornea and plasma. 
Latanoprost in free acid form is measurable in the aqueous humour within 4 hours of 
instillation. Approximately 1% of topically applied latanoprost is absorbed into the eye, the 
majority being absorbed into the systemic circulation through either conjunctiva vessels and 
nasal mucosa or gastrointestinal tract absorption. The peak concentration is reached about 2 
hours after topical instillation with the distribution volume of 0.16 ± 0.02 L/kg in humans 
(Sjöquist and Stjernschantz, 2002). The half-life of free acid in human plasma is about 17 
minutes. Plasma levels of latanoprost acid were below the detection limit in patients treated 
with latanoprost for a year. Latanoprost is metabolized by ǃ-oxidation in the liver; it is not 
metabolized in the cornea and is mainly excreted in the urine (88–98%). 
Although the exact mechanism of action of latanoprost is still uncertain, FP receptor plays 
essential role and FP receptor-deficient mice do not exhibit any pressure-lowering effect 
(Ota et al, 2005; Crowston et al, 2004). Aqueous humour production is not significantly 
affected by latanoprost but the most consistent finding is a substantial increase in 
uveoscleral (pressure-insensitive) outflow; a less consistent finding is the role in trabecular 
(pressure-sensitive) outflow capacity (Toris et al, 2008; Lim et al, 2008; Johnson et al, 2010). 
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There are 3 potential mechanisms by which latanoprost could increase uveoscleral drainage. 
These include: (1) Remodelling of extracellular matrix of the ciliary muscle and sclera 
causing permeability changes, (2) widening of the connective tissue-filled spaces among the 
ciliary muscle bundles, which may be caused by relaxation of the ciliary muscle and (3) 
changes in the shape of ciliary muscle cells as a result of altered actin and vinculin 
localization (Toris et al, 2008; Lindsey et al, 1997). The remodelling of extracellular matrix is 
believed to be responsible for sustaining the long-term pressure-lowering effect (Johnson et 
al, 2010). 
Ciliary muscle relaxation is believed to be responsible for the initial reduction of IOP but the 
effect is not prominent in latanoprost. Remodelling of the extracellular matrix within the 
ciliary muscle and sclera is the most thoroughly understood and most accepted mechanism. 
Latanoprost stimulates induction of Matrix Metallo-proteinases (MMP) 1, 2, and 3 that cause 
dissolution of collagen types I and III within the connective tissue-filled spaces between the 
outer longitudinal muscles (Lütjen-Drecoll and Tamm, 1988). Animal experimental studies 
showed evidence of changes in ciliary muscle; the tissue spaces of the ciliary muscle were 
enlarged and organized into tube-like spaces covered by endothelial-like cells with close 
basement membrane contact, and contained myelinated nerve fibre bundles that resembled 
a lymphatic system in the choroid (Krebs and Krebs, 1988; Richter et al, 2003).  
Latanoprost induced MMP 3, 9, 17, and TIMP 3, and down-regulated MMP 1, 2, 12, 14, 15, 
16, and TIMP 4. Latanoprost acid induced concentration-dependent increases in MMP 1, 3, 
and 9 gene transcriptions and a concentration- and time-dependent increase in TIMP 1 but 
not TIMP 2 mRNA and protein (Anthony et al, 2002). Cyclooxygenase (COX)-2 is also 
believed to play a role in the pressure-lowering effect of latanoprost (Sales et al, 2008). The 
mechanism of latanoprost-induced MMP secretion is through protein kinase C and 
extracellular signal-regulated protein kinase 1/2-dependent pathways (Chen et al, 2001). 
Mitogen-activated protein kinase and tumour necrosis factor ǂ-dependent signalling 
pathways may also be involved (Sardar et al, 2000). The vasodilatation effect of latanoprost, 
although minimal, is also postulated to play a role in facilitating uveoscleral outflow. 
Although increases aqueous outflow through non-conventional pathways seems to be 
responsible for the pressure-lowering effect of latanoprost, there are ongoing studies 
providing evidence of the possible role of trabecular meshwork outflow (Oh et al, 2006).  
In spite of uncertainty in the mechanism of latanoprost action, latanoprost is a clinically 
proven efficacious topical anti-glaucoma drug. Its effectiveness has been observed in many 
populations. Hedman and Larsson (2002), based on mean diurnal IOP reduction, found that 
latanoprost is more effective than timolol in 8 different populations with greater reduction 
among Mexican and Asian populations. A meta-analysis involving 1256 glaucoma patients 
found that latanoprost is superior to timolol in long-term IOP control (Zhang et al, 2001). 
Latanoprost has the advantage of achieving IOP reduction during both day and night while 
timolol has a minimal effect on nocturnal IOP (Larsson et al, 2002). In a long-term study, 
latanoprost sustained meaningful IOP reduction (Hedman et al, 2002). Latanoprost is not 
only effective in OAG but also in angle-closure glaucoma (Chew et al, 2004). In spite of its 
higher therapeutic index, there was a reported 18–25% non-responder rate (Scherer, 2002; 
Cheong et al, 2008; Camras and Hedmann, 2003). The definition of a responder varies 
according the predetermined cut-off point. Based on the US latanoprost study group, a 
greater proportion of patients classified as non-responders on any particular visit were 
responders on all other visits if treated with latanoprost rather than timolol (Camras and 
Hedmann, 2003). Among PG analogues, bimatoprost seems to be slightly superior in 
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reducing pressure but not without a price (van der Valk et al, 2005). Bimatoprost has a 
higher incidence of conjunctival hyperaemia.  
Although PGF2ǂ is responsible for stimulating bronchial hyper-responsiveness, respiratory 
impairment induced by latanoprost has not been reported (Hedner et al, 1997). Short half-
life and rapid clearance of the active latanoprost acid minimizes unwanted systemic side 
effects (Sjöquist and Stjernschantz, 2002). Furthermore, latanoprost free acids that enter the 
systemic circulation do not permeate tight-junction cell membrane barriers such as the 
blood-brain barrier, minimizing the potential for central nervous system side effects. 
However, some nonspecific systemic side effects such as headache, flulike syndromes, 
upper respiratory tract infections, and musculoskeletal pain have been reported (Alm et al, 
1995).  
Latanoprost-induced ocular side effects are a major concern. Conjunctival hyperaemia is a 
common side effect with the incidence range between 5 to 15% (Stewart et al, 2003; Walters 
et al, 2004). The incidence is much higher in travoprost and bimatoprost (Honrubia et al, 
2009; Walters et al, 2004). Conjunctival hyperaemia is generally mild and transient, and 
commonly develops within 1 month of therapy initiation. Vasodilation induced by 
prostaglandin promotes the release of nitric oxide that may be responsible for conjunctival 
hyperaemia (Alm et al, 2008). The saturated double bond in C13 and C14 of latanoprost is 
partly responsible (Resul and Stjernschantz, 1993). Ocular irritation, burning sensation, and 
dry eye are also reported (Stewart et al, 2003). However, the most intriguing side effect is the 
ability of latanoprost to induce pigmentation in the iris, eyelid, and eyelashes. Latanoprost-
induced iris darkening (LIID) was found in higher frequency in heterogeneous hazel irises 
and homogeneous gray and blue irises are less likely to develop LIID in Caucasians (Alm et 
al, 2008). Japanese and South East Asians, in spite of having homogeneous dark brown 
irises, were more likely to develop LIID (Chiba et al, 2004; Chou et al, 2005). During phase 
III of a latanoprost study, latanoprost was postulated to have the ability to promote iris 
melanocyte proliferation (Stjernschantz et al, 2002). However, there was no evidence of 
increases melanogenesis in tissue culture studies (Kashiwagi et al, 2002; Drago et al, 1999). 
Histopathological and morphometric studies found evidence of increased iris melanocytes 
in the stroma and redistribution of the melanocytes to the anterior iris stroma without a net 
increase in number (Cracknell and Gierson, 2009; Cracknell et al, 2003; Albert et al, 2008).  
LIID is irreversible and causes cosmetic concerns, especially when it occurs in one eye, but 
has no incapacitating visual side effects. Hyperpigmentation, elongation, and thickening of 
the eyelashes (hypertrichosis) may cause the lashes to touch the spectacles or cause 
difficulty in topical drug instillation but is never a major concern (Johnstone, 1997; Shaikh 
and Bodla, 2006). Unlike LIID, hypertrichosis is reversible and disappears several weeks 
after discontinuation of treatment. Peri-ocular hyperpigmentation is also reported and is 
most likely due to accidental spillover during drug administration (Herndon et al, 2003). 
Similar to hypertrichosis, the reversal of ocular hyperpigmentation was also reported even 
without discontinuation of treatment (Sharpe et al, 2007). There were also reported cases of 
hypo-pigmentation (Herndon et al, 2003).  
Disruption of the blood-aqueous barrier and posterior lens releases inflammatory mediators 
causes cystoids macular oedema (CME) following latanoprost treatment (Miyake et al, 
1999). Latanoprost-induced CME may cause visual impairment but the incidence is 
uncommon in comparison to the frequency of pigmentation-induced side effects (Warwar et 
al, 1998). Prostaglandin at higher concentrations acts as an inflammatory mediator and 
anterior uveitis was reported following latanoprost treatment (Warwar et al, 1998). 
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Reactivation of herpes simplex keratitis has been reported in 3 patients with a history of 
herpes simplex infection (Wand et al, 1999). In patients with a high risk of CME, anterior 
uveitis, and past history of herpes simplex, latanoprost is not recommended for glaucoma 
treatment. 
3.2 Topical Travaprost  
Travoprost (AL-6221) is an isopropyl ester of the (+) enantiomer of fluprostenol and 
chemically known as isopropyl (z)-7-[IR, 2R, 3R, 5S)-3, 5-dihydroxy-2-[ (IE, 3R)-3hydroxy-4-[ 
(ǂ, ǂ, ǂ-tri fluoro-m-tolyl) oxy]-1-butenyl) cyclopentyl]-5-heptenoate. Similar to latanoprost, 
travaprost is a prodrug that acts on FP receptor (Hellberg et al, 2001). It is believed through 
unknown mechanism, travaprost increase outflow through mainly unconventional pathway 
with some effect on conventional pathway (Torris et al, 2008). Unlike latanoprost, travaprost 
provides prolong pressure lowering effect up to 40 hours post single instillation (Fellman et 
al, 2002).  
Travoprost is reported to provide up to 28% pressure reduction from baseline, which is 
almost similar to latanoprost and significantly superior to timolol (Netland et al, 2001). 
However, travoprost provides lesser additional IOP reduction than bimatoprost in patients 
previously treated with latanoprost (Kammer et al, 2010). Similar to latanoprost, travaprost 
is efficacious in various type of glaucoma as monotherapy, adjunctive, replacement therapy 
and in fixed combination (Cheselita D, 2007; Orengo et al, 2001). 
A retrospective metanalysis study found that travoprost is superior to both latanoprost and 
timolol in African derived patients (Netland et al, 2003). Halpern et al (2002) found that 
travoprost not only more efficacious to timolol and latanoprost but also less likely to cause 
visual field progression in African derived patients. A prospective randomized study was 
conducted to study the potential of racial influence on efficacy of prostaglandin analogs, 
found no significant different between races and different type prostaglandin analogs (Birt 
et al, 2010). However, this study was hampered by small sample size. 
Conjunctival hyperaemia is the most common ocular side effect. The incidence and intensity 
was reported to be higher and more severe than in patients treated with latanoprost 
(Parmaksiz et al, 2006; Li N et al 2006). Prostaglandin induced iridial pigmentation (PIIP) is 
another common ocular side effect. Travaprost is a safe drug with no reported systemic side 
effect. 
3.3 Topical Bimatoprost 
Unlike latanoprost and travaprost, bimatoprost has ethyl amide group in the carbon-1 
position (Cantor, 2001). Chemical structure of bimatoprost is pharmacologically similar to 
prostaglandin F2ǂ ethanolamide, better known as prostamides. Prostamides are 
biosynthesized from endocannibinoid  anandamide by enzyme cyclo-oxygenase 2 (COX-2). 
Bimatoprost is a synthetic endogenous prostamides (Woodward et al, 2001). Bimatoprost 
acts on prostamide-sensitive receptor with minimal or no effect on prostaglandin F 
receptors. Bimatoprost as prostamide mimetic is fatty acid amide, which differs from fatty 
acid of prostaglandin (Woodward et al, 2003). Another striking difference from latanoprost 
and travaprost, it is not a prodrug (Woodward et al, 2001). There is no evidence of 
measurable free acid detected at the site of action in the eye. Therefore, hydrolysis is not 
required for bimatoprost to exert its pharmacological action. Latanoprost and travaprost 
require hydrolysis to free acid to act on FP receptor as agonist.  
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Bimatoprost produces more pronounced and prolonged pressure lowering effect. It is effective 
as monotherapy, adjunctive therapy, and replacement therapy and also as fixed combination 
with timolol. It was found to provide 35% pressure reduction in primary angle closure patients 
with 360° of posterior synechiae post ineffective laser peripheral iridotomy (Vyas et al, 2011). It 
is believed that bimatoprost acts on pressure sensitive and pressure insensitive outflow 
pathway (Brubaker et al, 2001). Latanoprost has minimal effect on pressure sensitive pathway; 
trabecular meshwork. Long term treatment of bimatoprost in animal experimental study has 
shown remodelling in uveoscleral as well as trabecular meshwork pathway. Similar to other 
prostaglandin analogs, bimatoprost produced significant better IOP reduction compared to 
timolol. In comparing between prostaglandin analogs, bimatoprost was found slightly 
superior to travaprost and latanoprost in pressure lowering medications. In addition, 
bimatoprost provides more constant IOP reduction and less fluctuation as compared to 
latanoprost and Timolol XE (Walters et al, 2004; Konstas et al, 2005). Fluctuation of IOP may 
cause further detrimental effect especially in already compromised optic nerve head. 
Bimatoprost has the edge for pressure lowering effect but reported higher incidence of 
conjunctival hyperaemia. The incidence of conjunctival hyperaemia was reported in 15-45% 
in patients treated with bimatoprost as monotherapy (Feldman, 2003). The most recent 
meta-analysis of 13 randomized control trials in 2222 glaucoma patients found significant 
higher incidence of conjunctival hyperaemia with bimatoprost compared to latanoprost 
(Honrubia et al, 2009). However, there is evidence to suggest that conjunctival hyperaemia 
decreases with time (Arcieri et al, 2005).  Other ocular side effects such as prostaglandin 
induced iridial pigmentation (PIIP), uveitis and cystoids macular edema are almost similar 
with other topical prostaglandin analogs.  
4. Carbonic anhydrase inhibitors 
Carbonic anhydrase inhibitor (CAI) was discovered by Becker in 1954 after several 
breakthrough findings. Bicarbonate was found to be an essential component of aqueous 
humour production and carbonic anhydrase enzyme was found in rabbit ciliary processes. 
Acetazolamide, a CAI, has gained popularity as an effective systemic anti-glaucoma 
medication when given orally or parenterally. Discontinuation of CAI is typically prompted 
by the occurrence of side effects such as general malaise, fatigue, depression, loss of 
appetite, weight loss, paraesthesia, and gastrointestinal disturbance. Intolerability to 
systemic CAI has been reported in 30% to 80% of patients, and is not ideal for long-term 
administration. In addition, devastating systemic side effects such as metabolic acidosis, 
hypokalaemia, and blood dyscrasia limit its usefulness. Haematological reactions such as 
agranulocytosis, aplastic anaemia, thrombocytopenia and neutropenia have also been 
reported (Fraunfelder et al, 1985). However, 40 years passed before the introduction of 
topical CAIs dorzolamide and brinzolamide, which have fewer unwanted extra-ocular side 
effects. The delay was due to failure to achieve 100% inhibition of carbonic anhydrase-II 
(CA-II), which is associated with poor ocular penetration. CA-II is an isoenzyme that plays 
an important role in the production of aqueous humour. The addition of an alkylamino side 
group improved the ocular penetration of topical CAI. 
Topical dorzolamide 2% or brinzolamide 1% monotherapy administered 2 or 3 times daily 
provides pressure reduction ranging from 21.8% to 26.2% (Lippa et al, 1991; Lippa et al, 
1992). Three applications per day provide better overall ocular hypotensive effect (Lippa et 
al, 1992). The combination of topical dorzolamide and oral acetazolamide failed to 
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demonstrate an additive effect (Rosenberg et al, 1998); therefore, combination therapy is not 
recommended as it may increase the risk of unwanted systemic side effects. Topical 
dorzolamide also provided further IOP reduction as adjunctive therapy with topical timolol, 
especially in gel solution (Adamsons et al, 1998a). The adjunctive effect of dorzolamide with 
topical timolol was similar to that of topical pilocarpine (4 times daily) but with better 
tolerability and compliance (Sthralman et al, 1996; Adamsons et al, 1998b). A fixed 
combination of 2% dorzolamide and 0.5% timolol, and 1% brinzolamide and 0.5% timolol 
was recently introduced; it is more efficacious than individual drug therapy and promotes 
better compliance (Boyle et al, 1998; Clineschmidt et al, 1998). Stinging, burning, or foreign 
body sensation and blurred vision are the most common ocular side effects. Others include 
superficial punctate keratitis, lid or conjunctival allergies, corneal oedema, and headache. 
Due to the effect of topical CAI on endothelium pump function, corneal edema has been 
reported especially in patient with underlying cornea problem such as guttata (Mathias et 
al, 2007). In fact, irreversible corneal decompensation following topical dorzolamide therapy 
has also been reported (Konowal et al, 1999). Systemic side effects similar to those associated 
with oral CAI have not been reported with dorzolamide, although bitter taste is reported.  
5. Topical adrenergic agonists 
Topical adrenergic agonists were introduced in the early 1920s when Hamburger (1923) 
applied topical epinephrine to patients with increased IOP. Epinephrine is a direct acting 
sympathomimetic amine with a combination of ǂ- and ǃ-adrenoreceptor-stimulating 
activities. The exact mechanism of the pressure-lowering effect of epinephrine is not fully 
understood. Based on evidence from fluorophotometry, tonography, and tonometry, 
epinephrine is believed to increase both conventional and unconventional outflow but 
certain observers found that uveoscleral outflow exceeded trabecular outflow (Weekers et 
al, 1955; Townsend and Brubaker, 1980; Schenker et al, 1981). Epinephrine may also 
stimulate aqueous humour production (Nagataki and Brubaker, 1981). ǃ-receptor 
stimulation is believed to occur through a cyclic AMP (cAMP)-dependent mechanism, as 
demonstrated in animal studies and an in vitro human eye outflow pathway perfusion 
model (Neufeld et al, 1979, Boas et al, 1981). Unlike pilocarpine, epinephrine induced slight 
mydriasis, conjunctival decongestion, and pressure reduction in glaucoma and ocular 
hypertensive patients. The effect of vasoconstriction and mydriasis is temporary; lasting 
only 2 to 12 hours, but the IOP reduction lasts longer. The effect on IOP is biphasic with 
transient IOP elevation followed by a hypotensive period.  
Epinephrine is no longer in use in many centres due to its low therapeutic index and its 
devastating ocular and systemic side effects. It was used as an additive or adjunctive drug at 
0.25% to 2% concentrations. Deposition of the epinephrine in ocular tissue including 
choroids, retina, and optic nerve, especially in aphakic patients is common (Kramer, 1980). 
In fact, it may also deposit in the heart and spleen following topical instillation, especially 
without punctual occlusion, and is almost comparable to parenteral administration. 
Prolonged use may result in localised pigment deposition (believed to contain epinephrine 
oxidation products such as adrenochrome) particularly in the palpebral conjunctiva and 
occasionally in the lid margin and cornea (Fong et al, 1993). Epinephrine maculopathy 
characterised by macular oedema, vascular spasm, and small cysts or fine haemorrhages 
may occur in aphakic patients (Michels and Maumenee, 1975). Fortunately, it is reversible 
upon treatment withdrawal but may cause alarming visual symptoms in affected patients. It 
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is also not recommended for glaucoma patients wearing soft contact lenses due to 
deposition of adrenochrome during treatment initiation. Systemic sympathomimetic effects 
such as palpitation, tachycardia, premature ventricular contractions, severe headache, and 
even hypertensive crisis may also occur (Ballin et al, 1966). In order to promote tolerability 
and reduce side effects, an epinephrine analogue was introduced as dipivefrin. Dipivefrin 
was the first pro-drug commercially available in ophthalmic practice (Mandell and Podos, 
1977). The lower concentration 0.1% of Dipivefrin is sufficient to achieve similar ocular 
hypotensive effects as 2% epinephrine with fewer ocular and systemic side effects.  
Selective ǂ2-adrenoreceptor agonists are replacing topical epinephrine; Apraclonidine and 
brimonidine have higher therapeutic indexes and fewer unwanted side effect. 
Apraclonidine, a relatively selective ǂ2-adrenoreceptor agonist, is chemically related to 
clonidine. Therefore, it reduces IOP and has a systemic hypotensive effect. Apraclonidine 
reduces IOP by suppressing aqueous humour production and enhancing uveoscleral 
outflow (Gharagozloo et al, 1988). It has a minimal effect on ocular blood flow because of its 
limited activity at the ǂ1 receptor. It is commercially available in 0.5% and 1.0% 
concentrations. Although 1.0% apraclonidine produces slightly better IOP reduction (up to 
31%) than the 0.5% solution (26%), the difference is statistically insignificant (Abrams et al, 
1989). However, most patients responded with at least 20% IOP reduction from baseline, 
making it an excellent additive medication (Toris et al, 1995; Araujo et al, 1995; Gross et al, 
1997). In fact, apraclonidine 0.5% 3 times a day for 90 days provides additional IOP 
reduction in glaucoma patients treated with concomitant timolol (Stewart et al, 1996). 
Through its ability to protect the blood-aqueous humour barrier, apraclonidine 1.0% is used 
to prevent a spike in IOP after cataract surgery or anterior segment laser surgery and as 
prophylaxis for post-cycloplegic IOP and for short-term IOP control prior to filtration 
surgery (Robin, 1989; Mori and Araie, 1992; Araie and Kiyoshi, 1993). Apraclonidine is not 
affected by the amount of ocular melanin. However, the effectiveness of apraclonidine is 
short-lived. The occurrence of tachyphylaxis and ocular allergy reduce its attractiveness for 
long-term treatment (Butler et al, 1995; Araoujo et al, 1995). 
As a relatively selective ǂ-adrenoreceptor agonist, apraclonidine also stimulates the ǂ1 
receptor. Stimulation of the ǂ1-adrenoreceptor is responsible for conjunctival hyperaemia, 
eyelid retraction, and a mild mydriatic effect (less than 1 mm). Ocular allergy is rare in 
short-term treatment but poses a major concern that warrants discontinuation in long-term 
therapy. Apraclonidine is also associated with dry mouth and dry nose, which limits its 
systemic absorption and reduces systemic side effect. The activity of brimonidine tartrate is 
similar to that of apraclonidine. Animal studies have shown that brimonidine may possess 
neuroprotective properties. However, unlike apraclonidine, brimonidine tartrate is a highly 
selective ǂ2-adrenoreceptor agonist with 30 times more selectivity than apraclonidine and 
reduced risk of ocular allergy. In fact, there is no evidence of cross-reactivity in patients 
allergic to apraclonidine who were switched to brimonidine (William et al, 2000; Shin DH et 
al, 1999). Thus, prescribing brimonidine in patients allergic to apraclonidine is safe and 
effective (Shin DH et al,1999). Brimonidine also binds to ocular melanin, which acts as drug 
reservoir, providing a slow-release effect. The pressure-lowering effect of brimonidine was 
almost equal to topical timolol in a short-term study.  
6. Pilocarpine 
Topical pilocarpine was the first topical pressure-lowering drug used in clinical practice. 
Pilocarpine, a direct-acting cholinergic agonist or parasympathomimetic, was introduced in 
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1876. An alkaloid derivative of natural plants, pilocarpine acts directly at neuro-effector 
junctions of the iris sphincter muscle and ciliary body causing pupillary constriction 
(miosis), spasm of accommodation, and reduction of IOP (Taylor, 1990). Although the 
precise mechanism of the pilocarpine effect has not been established, the most widely 
accepted explanation is that direct stimulation of the longitudinal muscle of the ciliary body 
causes widening of the trabecular spaces, facilitating aqueous humour outflow (Erikson and 
Schroeder, 2000). It is available in ophthalmic solution 0.5% to 10% and prescribed for 
application 4 times daily. There is an increasing hypotensive effect with increasing 
concentrations up to 4% in long-term therapy. Concentrations exceeding 4% provide 
minimal additional benefit. Due to its effect on ocular melanin, higher concentrations of 
pilocarpine are needed in darkly pigmented patients to achieve the same effect as in those 
with lighter-coloured irises (Harris and Galin, 1971). A sustained-release, membrane-bound 
drug delivery system (Ocusert) is available, which delivers pilocarpine at a controlled rate of 
20–40 µg/hour. A 4% ophthalmic gel is also available.  
IOP reduction up to 15% from baseline was observed in many types of glaucoma including 
POAG, PAC, PACG, and secondary glaucoma. The ability of pilocarpine to reduce or break 
the iridotrabecular contact in acute attacks of PAC is believed to be due to its miotic action. 
Its effectiveness in facilitating outflow has helped to sustain pilocarpine as a viable 
medication in glaucoma therapy. However, if the IOP exceeds 60 mmHg, pilocarpine has a 
limited effect on the iris sphincter, presumably because of ischaemia. It is widely used to 
stretch the iris in preparation for laser iridotomy and iridoplasty. Pilocarpine provides 
further IOP reduction in combination with topical beta blockers, CAI, adrenergic agonist 
and latanoprost (Airaksinen et al, 1987; Fristom and Nielson, 1993). 
The diminishing popularity of pilocarpine is partly due to the frequency of dosage required 
to achieve optimal results and to ocular side effects. The most troublesome ocular side effect 
is accommodative spasm, which may last for 2 to 3 hours and is frequently intolerable, 
especially in individuals less than 40 years old (Zimmerman, 1981). However, due to the 
aging process, a lesser effect on ciliary muscle contractility is seen in older patients. The 
miotic effect of pilocarpine can cause visual incapacitation and is unwelcome in patients 
with nuclear sclerotic and posterior sub-capsular cataract. Furthermore, long-term use of 
pilocarpine may hasten cataract development (Zimmerman and Wheeler, 1982). 
Paradoxically, although pilocarpine is used to break the iridotrabecular contact in PAC 
cases, there are reported cases of pupillary block induced by pilocarpine, which usually 
occurs in patients with narrow angles who have advancing cataract (Van Burskirk, 1982; 
Ritch, 1996). Other side effects include retinal detachment, allergic blepharoconjunctivitis, 
band keratopathy, iris cyst, and lid myokymia. Adverse systemic reactions to Ocusert are 
rare but may occur in patients with acute PAC or inadvertent drug leakage (Kushnick et al, 
1996). Headache, nausea, vomiting, diaphoresis, and weakness are possible systemic side 
effects and can be easily confused with symptoms of acute PAC (Zimmerman and Wheeler, 
1982). Other systemic side effects include increased salivation and lacrimation, diarrhoea, 
bronchiolar spasm, pulmonary oedema, systemic hypotension, and bradycardia 
(Zimmerman and Wheeler, 1982).  
7. Fixed combination 
Pressure lowering drugs therapy requires patient’s compliance to ensure the maximum 
effectiveness of the drugs especially in long term administration and even more challenging 
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in asymptomatic disease at the early stage glaucoma. The term of compliance is deemed 
inappropriate. Instead, adherence and persistence provide better description of patient’s 
behaviour toward medication instillation. Adherence is a measure of the degree of patient 
obeying pharmacotherapy instruction over a defined period of time (Schwartz and Quigley, 
2008). For example, if topical timolol is prescribed twice a day for a month but the patient 
only instilled 40 times, his/her adherence is 66%. Persistence is a measure of time to 
discontinuation. Accurate assessment of adherence and persistence is quite a challenge 
especially when most patients routinely overestimate their adherence (Friedman et al, 2008; 
Friedman et al, 2007). Poor adherence and persistence is associated with cost of the drug, 
tolerability, difficulty in instillation, lack of education, forgetfulness, denial, schedule and 
travel issues (Tsai et al, 2003; Friedman et al, 2008). ‘White coat adherence’ is another issue, 
in which patients are at their best adherence during 5 days prior to the follow up 
appointment; follow by a declining pattern until near to the next follow up (Feinstein, 1990). 
Frequency of dosing and complexity of the regimen also play important role. Poorer 
adherence is observed in those receiving adjunctive treatment (Nordstrom et al, 2005).  
Patients’ understanding of the importance of taking medication, their satisfaction with the 
drug, tolerability and cost is reflected by persistency. Persistence is not doing any better, 
ranging from 20% to 67% (Dasgupta et al, 2002; Spooner, 2002) and differs according to the 
class of pressure lowering drugs. Latanoprost, a prostaglandin analog has demonstrated 
better persistency compared to other drugs (Reardon et al, 2004; Schwartz et al, 2004). Thus, 
recently there is a sprouting of fixed combination pressure lowering treatment such as 
prostaglandin-beta blocker, carbonic anhydrase inhibitor-beta blocker and pilocarpine-beta 
blocker, which aim to improve adherence and persistence.  
Fixed combination therapy is based on the concept that different group of drugs act on 
different site of receptors or enzymes. It is postulated to provide additional pressure 
reduction of at least 15% from non-fixed combination. However, the pressure reduction with 
fixed combination is usually less than the sum of both drugs (Philip and Luc, 2000). The 
earliest fixed combination introduced in glaucoma management was beta-blockers and 
pilocarpine; 0.5% timolol and 2% pilocarpine, 0.5% timolol and 4% pilocarpine, and 0.1% 
metipranolol and 2% pilocarpine (Table 1.3). Pressure lowering effect of these fixed 
combination were found to be similar to the non-fixed combination or concomitant therapy 
(Maclure et al, 1989). The most important success in fixed combination of beta blockers and 
pilocarpine is convenience and reduction of instillation frequency of pilocarpine (Puustjärvi 
and Repo, 1992). 
Topical beta-blockers have been the most reliable pressure lowering drug for many decades. 
Currently, beta blockers not only used as the gold standard for comparative studies with 
other medications but also the most popular for fixed combination therapy. The success of 
fixed combination of beta blockers and pilocarpine has later inspired the drug 
manufacturers to produce other fixed combination (table 1.3). Fixed combination therapy 
provides additional option for ophthalmologists but the actual impact in clinical practice is 
not well established.  
Comparison of the fixed combination therapy with monotherapy of individual drug has 
shown promising result. Fixed combination of 0.5% timolol and 2% dorzolamide provides 
an additional 13 to 20% pressure reduction at peak and 5 to 14% at through compared to 
timolol monotherapy (Strohmaier et al, 1998; Boyle et al, 1998). Fixed combination of 0.5% 
timolol and 0.2% brimonidine has also shown significantly better pressure lowering effect of 
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4.4 to 7.6 mmHg as compared to brimonidine and timolol individually. Most important 
advantage of fixed combination timolol-brimonidine is lesser side effect compared to 
brimonidine monotherapy but increase compared to timolol monotherapy (Mark et al, 
2006). 
 
Brand name Constitutents Preservatives 
Timpilo-2® 0.5% Timolol maleate + 2%Pilocarpine hydrochloride BAK 
Timpilo-4® 0.5% Timolol maleate + 4%Pilocarpine hydrochloride BAK 
Normoglaucon® 0.1% Metipronalol +  2% Pilocarpine hydrochloride  BAK 
Cosopt® 0.5% Timolol maleate + 2% Dorzolamide 
hydrochloride 
BAK 
Azarga® 0.5% Timolol maleate + 1% Brinzolamide BAK 
Combigan® 0.5% Timolol maleate + 0.2% Brimonidine tartrate BAK 
Duo Trav® 0.5% Timolol maleate + 0.004% Travaprost BAK 
Ganfort® 0.5% Timolol maleate + 0.03% Bimatoprost  BAK 
Xalacom® 0.5% Timolol maleate + 0.005% Latanoprost BAK 
BAK: benzalkonium chloride 
Table 1.3: Fixed combination of pressure lowering drugs 
It is seem unfair to compare the fixed combination therapy with monotherapy treatment. 
Fixed combination is basically mixing the two drugs together, how the individual 
constituent of the drugs is adjusted or mixed is not known. The possibility of drug-drug 
interaction and drug-preservative interaction is not well established. Majority of clinical 
data available are on the comparison between fixed combination and concomitant therapy 
(Khouri et al, 2007). The efficacy of fixed combination and concomitant therapy is 
controversial. There are evidences that suggest the superiority of fixed combination 
(Diestelhorst and Larsson, 2004; Schuman et al, 2005). On the other hand, there are adequate 
evidences to suggest otherwise (Strohmaier et al, 1998; Diestelhorst and Larsson, 2006; 
Hughes et al, 2005). However, there are many factors such time of IOP measurement, time of 
instillation, diurnal variation and the possibility of wash out period that are not taken into 
consideration and lead to over or underestimation (Khouri et al, 2007).  
A systematic review involving seven randomized controlled trials on various fixed 
combination with 0.5% timolol; travaprost, latanoprost, dorzolamide and brimonidine found 
that the concomitant treatment with individual drug has the edge in efficacy. However, the 
difference failed to exert pre-determined non-inferiority measure of ≤1.5mmHg upper 
confidence limit (Cox et al, 2008). Similar outcome is also noted in another systematic review 
and metanalysis of 29 studies involving fixed combination of prostaglandin analogs and 
timolol (Webers et al, 2010). Fixed combination therapy has advantages over multiple drop 
and multiple bottle therapy, improving patient convenience and adherence and perhaps more 
economical in a long run. However, the efficacy is still doubtful especially in advance cases 
when 1mmHg pressure reduction is meaningful. Prescription of fixed combination therapy 
needs to be tailored and customized according to patients.  
8. The impact of topical pressure lowering drugs on glaucoma surgery 
Apart from adherence and persistence problem, topical pressure lowering drug may 
potentially induced subclinical conjunctival inflammation. Subclinical conjunctival 
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inflammation is believed to be associated to the success of trabeculectomy. Long term and 
multiple treatments of topical pressure lowering drugs are believed to induce subclinical 
inflammation of the conjunctival that may induce excessive scarring of the bleb and 
eventually responsible for trabeculectomy failure (Sherwood et al, 1989; Broadway et al, 
1994a; Broadway et al, 1994b). The histological evidence is inconsistent. Although there is 
evidence that suggest pressure lowering drugs induced mark increased in inflammatory 
markers and macrophages, there is also evidence against it (Sherwood et al, 1989; Broadway 
et al, 1994a; Baun et al, 1995; Liza-Sharmini et al, 2007). In addition, it is still not clear 
whether the active ingredient or the preservative exerts more detrimental effect. 
Benzalkonium chloride, the most common preservative used in topical antiglaucoma 
medication has been implicated to cause elevation of inflammatory markers in tissue culture 
and animal models (De Saint Jean et al, 1999; Debbasch et al, 2001; Becquet et al, 1998). 
Preservative free timolol was found to express less interleukins and inflammatory markers 
(Baudouin et al, 2004). On the other hand, sympathomimetics has been postulated to induce 
significant conjunctival cell profile changes and associated with poorer trabeculectomy 
outcome (Broadway et al, 1994a). In fact, discontinuation of sympathomimetics and steroid 
treatment has been proven to reverse this silent effect of pressure lowering medication 
(Broadway et al, 1996). Medical treatment versus surgical intervention as the first line 
management of glaucoma is still debatable.  
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